The global psoriasis drug market is experiencing explosive growth, projected to reach US$27.57 billion by 2034. Driven by increasing prevalence, R&D investment, and innovative treatments, this market analysis reveals key trends, leading players, and future projections.
This comprehensive guide delves into the causes, treatments, and expert advice for managing common skin conditions like eczema, psoriasis, and pigmentation. Learn about the best practices from GPs, dermatologists, facialists, Traditional Chinese Medicine practitioners, and nutritionists to achieve healthier, more radiant skin.
Singer Kelly Key used her platform to bring attention to psoriasis on World Psoriasis Day, sharing her personal journey and encouraging others to learn more about the chronic skin condition. She will be hosting a live discussion with a dermatologist to discuss the challenges and care associated with psoriasis.
HC Wainwright has initiated coverage on Alumis Inc. (ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases, with a Buy rating and a $30 price target. The firm is bullish on Alumis’ lead drug candidate, ESK-001, a TYK2 inhibitor currently in Phase 3 trials for psoriasis and Phase 2 trials for systemic lupus erythematosus. HC Wainwright believes ESK-001 possesses superior efficacy and selectivity compared to existing TYK2 inhibitors like Sotyktu (deucravacitinib), potentially capturing a significant market share.
